Roche, Novartis slam Italian cartel fine
This article was originally published in Scrip
Roche and Novartis have reacted angrily to a decision by the Italian Competition Authority to fine them €182.5m for what it described as "illicit collusion" to exclude Roche's Avastin from the ophthalmology market in favor of Novartis's similar drug Lucentis.
You may also be interested in...
In the latest in a string of knockbacks for both Novartis and Roche, the EU’s highest court has said that the Italian authorities are within their rights to reimburse Roche’s Avastin for wet AMD, even though it is not approved for that indication.
In the latest development in the long-running case pitting Novartis and Roche against the Italian competition authority over a fine imposed in 2014, the Court of Justice of the EU has confirmed that the firms’ arrangement over Avastin and Lucentis could constitute a serious restriction on competition if it involved the dissemination of misleading information. The case now goes back to the Italian court.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.